Table 1 Summary of selected ongoing immunotherapy clinical trials in gastrointestinal malignancies
From: Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
NCI identifier | Study phase | Study agent | Mode of action of immunotherapy agent |
|---|---|---|---|
Esophageal cancer | |||
NCT02642809 | 0 | Pembrolizumab + radiotherapy | Anti-PD-1 Ab |
NCT02735239 | I/II | Durvalumab + chemotherapy ± radiotherapy | Anti-PD-L1 Ab |
NCT02559687 (KEYNOTE-180) | II | Pembrolizumab | Anti-PD-1 Ab |
NCT02644863, NCT01691625 | II | Chemotherapy ± autologous dendritic cells and cytokine-induced killer cells (DC-CIK) | Adoptive cellular therapy |
NCT02564263 (KEYNOTE-181) | III | Pembrolizumab vs. chemotherapy | Anti-PD-1 Ab |
Gastric cancer | |||
NCT02443324 | I | Pembrolizumab + ramucirumab | Anti-PD-1 Ab, anti-VEGFR2 Ab |
NCT02310464 | I | OBI-833 | Cancer vaccine |
NCT02689284 | Ib/II | Pembrolizumab + margetuximab | Anti-PD-1 Ab, anti-HER2-neu Ab |
NCT02340975 | Ib/II | Tremelimumab vs. durvalumab vs. tremelimumab + durvalumab | Anti-CTLA-4 Ab, anti-PD-L1 Ab |
NCT02317471 | I/II | Autologous gp96 vaccination ± chemotherapy | Heat shock protein purified from autologous tumor cells |
NCT02617134 | I/II | Anti-MUC1 CAR T cells | Adoptive cellular therapy |
NCT02862561, NCT02873520 | I/II | Precision cell immunotherapy ± chemotherapy | Dendritic cell suspension |
NCT01783951 | I/II | DC-CIK + S-1 | Adoptive cellular therapy |
NCT02632201 | I/II | Pluripotent killer T cells expressing Ab for HER-2 (PIK-HER2) | Adoptive cellular therapy |
NCT02370498 (KEYNOTE-061) | III | Pembrolizumab vs. paclitaxel | Anti-PD-1 Ab |
NCT02494583 (KEYNOTE-062) | III | Pembrolizumab vs. pembrolizumab/cisplatin/5-FU vs. placebo/cisplatin/5-FU | Anti-PD-1 Ab |
NCT02625610 (JAVELIN Gastric 100) | III | Avelumab vs. chemotherapy | Anti-PD-L1 Ab |
NCT02625623 (JAVELIN Gastric 300) | III | Avelumab + BSC vs. chemotherapy + BSC | Anti-PD-L1 Ab |
Colorectal cancer | |||
NCT02512172 | I | Pembrolizumab + romidepsin and/or 5-azacitidine | Anti-PD-1 Ab |
NCT02856425 | I | Pembrolizumab + nintedanib | Anti-PD-1 Ab |
NCT02777710 | I | Durvalumab + CSF-1R TKI | Anti-PD-L1 Ab |
NCT02754856 | I | Durvalumab + tremelimumab | Anti-PD-L1 Ab, anti-CTLA-4 Ab |
NCT02559024 | I | MEDI6469 | Anti-OX40 Ab |
NCT01890213 | I | AVX701 | CEA-based cancer vaccine |
NCT02617134 | I/II | Anti-MUC1 CAR T cells | Adoptive cellular therapy |
NCT02900664 | Ib | PDR001 + either CJM112 or EGF816 or canakinumab or trametinib | Anti-PD-1 Ab |
NCT02460198 (KEYNOTE-164) | II | Pembrolizumab | Anti-PD-1 Ab |
NCT02860546 | II | Nivolumab + TAS-102 | Anti-PD-1 Ab |
NCT02466906 | II | RhGM-CSF | Recombinant human GM-CSF |
NCT02448173 | III | OncoVAX + surgery | Cancer vaccine |
NCT02563002 (KEYNOTE-177) | III | Pembrolizumab vs. chemotherapy | Anti-PD-1 Ab |
NCT02788279 | III | Atezolizumab ± cobimetinib vs. regorafenib | Anti-PD-L1 |
NCT02280278 | III | CIK | Cytokine-induced killer cells |
Pancreatic cancer | |||
NCT02734160 | I | Durvalumab + galunisertib | Anti-PD-L1 Ab |
NCT02529579 | I/II | Gemcitabine ± iAPA-DC/CTL | Adoptive cellular therapy |
NCT02718859 | I/II | NK cells + irreversible electroporation | Natural killer cells |
NCT02305186 | I/II | Chemoradiation ± pembrolizumab | Anti-PD-1 Ab |
NCT01781520 | I/II | DC-CIK + S-1 | Adoptive cellular therapy |
NCT01896869 | II | FOLFIRINOX + ipilimumab + allogeneic GM-CSF vaccine | Anti-CTLA-4 Ab, vaccine |
NCT02648282 | II | Cyclophosphamide + pembrolizumab + GVAX + SBRT | Anti-PD-1 Ab, vaccine |
NCT02558894 | II | Durvalumab ± tremelimumab | Anti-PD-L1 Ab, anti-CTLA-4 Ab |
NCT02243371 | II | GVAX + CRS-207 ± nivolumab | Vaccine, anti-PD-1 Ab |
Hepatocellular carcinoma | |||
NCT02843802 | I/II | NK cells + cryosurgery | Natural killer cells |
NCT02873442 | I/II | Precision cells + TACE | Dendritic cell suspension |
NCT02239900 | I/II | Ipilimumab + SBRT | Anti-CTLA-4 Ab |
NCT01658878 | I/II | Nivolumab; nivolumab + ipilimumab | Anti-PD-1 Ab, anti-CTLA-4 Ab |
NCT02839954 | I/II | CAR-pNK cell | Adoptive cellular therapy |
NCT02632006 | I/II | PIK-PD-1 cells | Adoptive cellular therapy |
NCT02715362 | I/II | GPC3-CAR T cells | Adoptive cellular therapy |
NCT02702414 | II | Pembrolizumab | Anti-PD-1 Ab |
NCT02519348 | II | Durvalumab + tremelimumab vs. durvalumab vs. tremelimumab | Anti-PD-L1 Ab, anti-CTLA-4 Ab |
NCT02487017 | II | TACE ± DC-CIK | Adoptive cellular therapy |
NCT02256514 | II | Hepcortespenlisimut-L | Cancer vaccine |
NCT01174121 | II | Autologous tumor infiltrating lymphocytes (TILs) | Adoptive cellular therapy |
NCT02562755 | III | Sorafenib ± Pexa-Vec | Vaccinia virus-based cancer vaccine |
NCT02576509 | III | Nivolumab vs. sorafenib | Anti-PD-1 Ab |
NCT02702401 (KEYNOTE-240) | III | Pembrolizumab vs. BSC | Anti-PD-1 Ab |
NCT02232490 | III | Hepcortespenlisimut-L vs. placebo | Cancer vaccine |